Article

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer’s disease

2024-11-02

Abstract excerpt

<h4>Background</h4> All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e0456f81-20e9-596e-91e1-8627a1f0cee0
DOI: 10.1101/2024.10.31.24316469

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer’s diseaseDOI 10.1101/2024.10.31.24316469Read

Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's diseaseSemantic proximity Read

Automated Plasma Phospho-tau217 Assays for the diagnosis of Down Syndrome-Related Alzheimer's DiseaseSemantic proximity Read

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudySemantic proximity Read

Increased levels of plasma total tau in adult Down syndromeSemantic proximity Read

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodologySemantic proximity Read

Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increaseSemantic proximity Read

Aging in Down Syndrome and the Development of Alzheimer's Disease NeuropathologySemantic proximity Read

Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndromeSemantic proximity Read

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approachSemantic proximity Read

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discoverySemantic proximity Read

Aging with Down Syndrome—Where Are We Now and Where Are We Going?Semantic proximity Read

Longitudinal investigation for enhancing Down Syndrome Research (LIFE‐DSR) Study: Tau PET and CSF sub‐studiesSemantic proximity Read